Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT03931330 Completed - Clinical trials for Irritable Bowel Syndrome

Does Improving Vagal Tone Increase Mitochondrial Bioenergetics

Start date: February 6, 2019
Phase: N/A
Study type: Interventional

This study evaluates the effect of auricular neurostimulation on mitochondrial bioenergetics and inflammation through vagal nerve modulation via non-invasive percutaneous electrical nerve field stimulator in children with functional gastrointestinal disorders.

NCT ID: NCT03931291 Completed - Clinical trials for Acute Myeloid Leukemia or Myelodysplastic Syndromes

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Start date: September 16, 2019
Phase: Phase 2
Study type: Interventional

A multi-center, open label, Phase II clinical trial to assess the safety and efficacy of APR-246 in combination with azacitidine as maintenance therapy after allogeneic HSCT (hematopoietic stem cell transplant) for patients with TP53 mutant AML or MDS.

NCT ID: NCT03930914 Completed - Clinical trials for Postural Orthostatic Tachycardia Syndrome

Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome

POTS
Start date: November 4, 2019
Phase: N/A
Study type: Interventional

Postural orthostatic tachycardia (POTS) is characterized by abnormalities in the autonomic nervous system in the body. The autonomic nervous system controls and regulates body functions such as heart rate, breathing, digestion, and more. The investigator has shown that patients with POTS have higher cardiovascular and adrenergic activating autoantibodies (AAb), which likely changes the normal make-up of POTS. There are autoantibodies that have been suggested by a few reports of their presence in POTS, but their role different aspects of POTS is unknown. The study will look at the body's responses in patients with POTS. The crossover study design is to have half of the patients will start with sham followed by active stimulation and half will start by active followed by sham stimulation. It is anticipated that results will provide a potential therapeutic approach based on the understanding of POTS.

NCT ID: NCT03929211 Withdrawn - Clinical trials for Myelodysplastic Syndromes

CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

Start date: May 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 study of the combination of CPI-613 and hydroxychloroquine for the treatment of high risk myelodysplastic syndrome patients who have failed a hypomethylating agent.

NCT ID: NCT03926286 Completed - Sjogren's Syndrome Clinical Trials

Fecal Microbial Transplant (FMT) for Sjogrens Syndrome

Start date: April 15, 2019
Phase: Phase 1
Study type: Interventional

This is an open label study to evaluate the effect of Fecal Microbiota Transplantation (FMT) on the gut microbiome and Systemic parameters.

NCT ID: NCT03923322 Not yet recruiting - Clinical trials for Irritable Bowel Syndrome Characterized by Constipation

Botanical Tincture for Symptoms of Irritable Bowel Syndrome

Start date: December 2023
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to investigate the feasibility of a follow-up larger RCT on the efficacy of Botanical Tincture to relieve abdominal pain in people with Irritable Bowel Syndrome Constipation Predominant (IBS-C).

NCT ID: NCT03923244 Completed - Dry Eye Syndrome Clinical Trials

Dry Eye Syndrome Description During Cataract Surgery, With Multimodal Analysis of the Ocular Surface

C-SS0
Start date: April 1, 2019
Phase: N/A
Study type: Interventional

The main objective is to describe the characteristics of dry eye syndrome before and after surgery at one month of cataract surgery, using a multimodal analysis of the ocular surface. The secondary objectives are to evaluate: - Predictive factors of dry eye syndrome during cataract surgery: - The characteristics of dry eye syndrome - Implications for the patient's quality of life

NCT ID: NCT03923140 Recruiting - Clinical trials for Cryopyrin-Associated Periodic Syndromes

A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)

Start date: May 23, 2019
Phase: Phase 2
Study type: Interventional

This is a prospective cohort study to observe the efficacy and safety of tranilast in CAPS patients. The investigators would analyze the changes in Auto-Inflammatory Diseases Activity Index (AIDAI) before and after treatment as well as changes in inflammatory markers, patients' and physician's global assessment of disease activity to determine the efficacy and safety of tranilast.

NCT ID: NCT03922165 Completed - Down Syndrome Clinical Trials

Healthy Sleep for Children With Down Syndrome

HELP-DS
Start date: May 22, 2019
Phase:
Study type: Observational

The purpose of this multi-center observational study (utilizing the sites enrolling patients for the Pediatric Adenotonsillectomy Trial for Snoring (PATS) [1U011HL125307-O1A1]) is to gather data regarding children with Down syndrome (DS) and Sleep Disordered Breathing (SDB) referred for treatment with adenotonsillectomy to inform a future randomized controlled trial in this population.

NCT ID: NCT03922139 Terminated - Clinical trials for Compartment Syndrome of Leg

Botox for the Treatment of Chronic Exertional Compartment Syndrome

Start date: October 8, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

After diagnosis of Chronic Exertional Compartment Syndrome (CECS), the participants will be referred to both physical therapy and Botox injection. In physical therapy, the therapist will perform strength measurements of the lower leg (ankle plantarflexion and dorsiflexion) which will be repeated 2 months following the injection. An ultrasound-guided injection of 50 units of Botox will be administered into the tibialis anterior. 25 units will be injected into two different spots in the muscle one being more proximal and the other distal. This will be a one-time injection and will be observed as to how it effects participant symptoms over the next 6 months at either a clinic visit (at 2 months) or telephone call (at 4 and 6 months after injection) via the University of Wisconsin Running Index. Two months following the injection, the participant will undergo repeat measurements of strength using the Kiio Force Sensor. Should potential participants of childbearing potential wish to enroll in the study, a urine pregnancy test will be performed prior to enrollment; participants will not be enrolled if test is positive.